Alzheimer's Disease and the Path Forward

Alzheimer’s: The Puzzle, The Partners, The Path Forward

Join Us for a Discussion about Challenges and Opportunities In Pre-Competitive Partnerships, Clinical Trial Enrollment and Public Policy

WASHINGTON, DC (September 23, 2013) – Please join the Pharmaceutical Research and Manufacturers of America (PhRMA), the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation at an October 23, 2013 forum focused on the primary hurdles to combating Alzheimer’s Disease (AD), a debilitating neurodegenerative disease that currently afflicts more than 5 million people in the U.S. 

In an effort to catalyze progress in AD innovation and move medical science closer to our shared goal of bringing new preventative and therapeutic solutions to Alzheimer’s patients, we are convening top industry and academic scientists, patients, policymakers, and other stakeholders for a day of open engagement and dialogue. Key topics of focus will include how to accelerate the impact of pre-competitive collaborative partnerships, challenges currently facing clinical trial recruitment specific to Alzheimer’s and new paths forward for science and policy.  During the lunch, we will also feature patient stories about the devastating impact this disease has on families and communities across the U.S. 

Who:    Suzanne Corker, PhD, Professor of Behavioral Neuroscience, Emerita, Massachussetts Institute of Technology

                 Neil Buckholtz, PhD, Director, Division of Neuroscience Office, National Institute on Aging

                 Bill Chin, MD, Executive Vice President, Scientific & Regulatory Affairs, PhRMA;

                 Howard Fillit, MD, Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation

                 Maria Freire, PhD, President, Foundation of NIH;

                 Tim Garnett, MD, Chief Medical Officer and Senior Vice President, Eli Lilly;

                 Nicholas Kozaur, MD, Acting Clinical Team Lead at the FDA’s Division of Neurology Products;

                 Eric Parker, PhD, Executive Director and Neuroscience Site Lead, MerckResearch Laboratories;

                 Heather Snyder, PhD, Director, Medical and Scientific Relations, Alzheimer’s Association;

                 Stevin Zorn, PhD, Executive Vice President of R&D, Lundbeck;

                 And others

           

What:   Alzheimer’s: The Puzzle, The Partners, The Path Forward

                Sponsored by: PhRMA, the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation

 

When:  Wednesday, October 23, 2013, 9:00am – 5:45pm

 

Where:  National Academy of Sciences Building

                  2102 Constitution Ave., NW

                  Washington, DC 2003

 

*** Due to limiting seating capacity, please fill out the registration form found on http://www.phrma.org/projectcures by October 16, 2013.    


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org

More On PhRMA — powered by PhRMApedia